RUO

Peptisynlab · Research Compound

Tirzepatide 20mg

Synthetic dual incretin peptide with balanced agonism at GLP-1 and GIP receptors. The reference dual-agonist of the incretin class — extensively characterized in metabolic, glycemic and weight-management research.

GLP-1 / GIP Dual Agonist RUO

CAS Number: 2023788-19-2
Molecular Formula: C225H348N48O28
Molecular Weight: 4812.64 g/mol
Purity: ≥ 99% HPLC
Vial Content: 20 mg lyophilized
Form: White lyophilized powder

Half-life ~5 days Once-weekly dosing intervals in research

Reconstitution 2 mL bac water Yields 10 mg/mL working concentration

Storage −20 °C / 2–8 °C Lyophilized: −20 °C · Reconstituted: 2–8 °C

Route (Research) Subcutaneous Standard route in published literature

Overview

Tirzepatide is a 39-amino-acid synthetic peptide engineered to act as a balanced dual agonist at the GLP-1 and GIP incretin receptors. As the first-in-class dual incretin molecule, it has set the benchmark for metabolic-research peptides and remains the most heavily referenced compound in incretin pharmacology.

The peptide backbone derives from the GIP sequence, modified with a fatty di-acid (C20) side chain that binds plasma albumin, extending its half-life to several days. This albumin-anchoring strategy allows once-weekly dosing in research models — comparable to retatrutide and semaglutide.

Mechanism of Action — How It Works

Tirzepatide engages two complementary metabolic receptors at biased ratios. The dual stimulation produces an additive effect on insulin secretion, satiety and adipose tissue function.

GLP-1 Receptor

Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and centrally mediated appetite reduction.

GIP Receptor

Amplifies the insulin response to nutrient intake and modulates lipid storage in white adipose tissue, contributing to improved adipocyte function.

Central Appetite Modulation

Acts on hypothalamic circuits that regulate hunger and satiety, lowering caloric intake in research models.

Albumin Binding

The C20 fatty di-acid side chain binds plasma albumin, extending circulating half-life to roughly 5 days.

Research Effects on the Body

Reported endpoints in published metabolic-research literature.

Body weight reduction: robust dose-dependent reductions in clinical and pre-clinical research models.
Glycemic control: significant improvements in fasting glucose, post-prandial glucose and HbA1c-equivalent endpoints.
Insulin sensitivity: measurable improvements in markers of peripheral insulin sensitivity.
Appetite suppression: reduced food intake and meal frequency through GLP-1 central action.
Peptisynlab profile: reductions in triglycerides and improvements in lipoprotein markers.
Hepatic fat: reductions in liver fat content reported in metabolic-imaging studies.

Reconstitution — Dilution Math

Tirzepatide is supplied lyophilized. Reconstitute with bacteriostatic water (0.9% benzyl alcohol). Volumes shown for the standard 20 mg vial — units refer to insulin syringe (1 mL = 100 IU).

Bac Water	Concentration	2.5 mg dose	5 mg dose	10 mg dose
1 mL	20 mg/mL	0.125 mL · 12.5 IU	0.25 mL · 25 IU	0.5 mL · 50 IU
2 mL	10 mg/mL	0.25 mL · 25 IU	0.5 mL · 50 IU	1.0 mL · 100 IU
4 mL	5 mg/mL	0.5 mL · 50 IU	1.0 mL · 100 IU	—

Standardized 20 mg working reference: a 1 mL reconstitution gives 20 mg/mL — the same baseline used across the Peptisynlab catalog for cross-compound comparison.

Dosing Reference (Research Context)

Dose ranges below are from published clinical-research literature, listed for laboratory reference only.

Phase	Reported Range	Typical Frequency	Vial Duration (20 mg)
Initial / titration	2.5 mg	Once weekly	~8 weeks
Mid-range	5 – 10 mg	Once weekly	2 – 4 weeks
High-end research	12.5 – 15 mg	Once weekly	~1 – 2 weeks

Half-Life, Onset and Duration

Half-life: approximately 5 days.

Onset: measurable receptor activation within hours; sustained metabolic effects observable within the first dose cycle.

Duration of effect: covers the full week between doses. Steady-state plasma concentrations reached after roughly 4 weeks of consistent dosing.

Wash-out: approximately 25 days for full clearance after discontinuation (5 × half-life).

Storage & Stability

Lyophilized vial: store at −20 °C for long-term stability. Refrigeration (2–8 °C) acceptable for short-term storage.
Reconstituted solution: store at 2–8 °C; use within 28 days. Do not freeze after reconstitution.
Light: protect from direct light.
Handling: swirl gently to dissolve; avoid vigorous shaking.

Important Considerations

Research Use Only. Information presented is for in-vitro and laboratory-research contexts. Tirzepatide on this site is not a finished pharmaceutical product, is not intended for diagnosis, treatment or prevention of disease, and is not for human or veterinary use.